Company profile

When your clinical trial has to Overachieve in Central and Eastern Europe, HungaroTrial is here to help. Providing services for Phase 1 through Phase 4 clinical trials in Hungary, Czech Republic, Slovakia, Romania, Serbia, Croatia, Ukraine and Russia, HungaroTrial is the CEE region’s leading independent CRO.

To Overachieve, your clinical trial needs the best minds from beginning to end. That’s why Hungarotrial’s full-time staff includes 12 MDs of various specialties,more than any other independent CRO in the region. And you can be assured that our experienced team has built strong relationships with the most respected Key Opinion Leaders in CEE.

Our staff’s broad medical experience means that your clinical study benefits from diverse skills and synergistic teamwork.  Over the past 10 years, HungaroTrial has become well known not just for this broad expertise, but also for our deep experience in Oncology, Rheumatology, Cardiovascular diseases, PAO, CNS and some other focus therapeutic areas.

In the news

HungaroTrial CRO was most recently featured in a March 2013 interview with CEbiotech.com, the Central European Biotechnology Portal, to discuss its successes as a CRO and how it has been able to achieve this success throughout its 13 year history.

What do you think has been your biggest achievement since the establishment of the company?

To define only one achievement would be difficult as we have had many successes in our        13 year history here in CEE.  However, what we consider to be most important is the consistent trust bestowed upon us by biotech and pharmaceutical companies from the United States to carry out studies in the region.  This respect strengthens our worldwide reputation and brings repeat clients from the EU and US.”

http://cebiotech.com/articles/Speed-of-growth-is-a-difficult-balance-the-interview-with-michael-globits-business-operations-manager-of-hungarotrial,134

 

 

In May 2010, HungaroTrial was mentioned in the prestigious GEN – Genetic Engineering & Biotechnology News journal, highlighted among the rising stars of the Hungarian biotech scene and portrayed as a prominent regional CRO in Central and Eastern Europe.

"Hungary is a good location for clinical trials, so HungaroTrial, a CRO for Phases I to IV, is doing well. It has been profitable from the start and has carried out 63 clinical trials in CEE countries, CEO Lajos Sarosi, M.D., says. It is also developing business in the U.S. and counts Roche, GSK, Wyeth, and Sanofi-Aventis among its customers. It will soon start work in Ukraine, Kazakhstan, and Russia. "These countries are to play a significant role in clinical research," predicts Dr. Sarosi."

http://www.genengnews.com/gen-articles/hungary-bids-for-prime-spot-in-eu-biotech/3272/?page=2

Company Fact Sheet

Year of establishment: 1999

Ownership: Private
Management stock options: Yes

Number of employees: 70+
Number of MDs employed: 12

Local offices:
Hungary
Romania
Slovakia
Serbia

Remote operations:
Czech Republic
Croatia
Bosnia
Ukraine
Russia
Bulgaria
Poland

Number of clinical projects managed: 120
Number of sponsor audits: 48
Number of regulatory inspections: 8


Copyright: HungaroTrial 2014